港股異動 | 加科思-B(1167.HK)高開4.32% KRASG12C抑制劑新藥臨牀實驗申請在中國獲批
格隆匯5月28日丨加科思-B(1167.HK)高開4.32%,報21.75港元,最新市值167億港元。加科思今日早間公佈,公司JAB-21822項目KRASG12C抑制劑的新藥臨牀試驗申請(IND)已於2021年5月27日獲得中國國家藥品監督管理局藥品審評中心(CDE)批准,此前該項目IND已於2021年5月3日獲得美國FDA批准。JAB-21822是公司自主研發的創新變構抑制劑,旨在針對KRASG12C突變。它將用於治療KRASG12C突變的晚期實體瘤,包括但不限於非小細胞肺癌(NSCLC),結直腸癌(CRC)等晚期實體瘤。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.